Summary

Eligibility
for females ages 18 years and up (full criteria)
Location
at UC Irvine UCSD
Dates
study started
completion around
Principal Investigator
by Hilary Shapiro, MD (ucsd)Afshan Hameed, MD (uci)

Description

Summary

The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.

Official Title

Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)

Details

Keywords

Peripartum Cardiomyopathy, Postpartum, Cardiomyopathies, Bromocriptine, Rivaroxaban, Guideline Directed Medical Therapy for Heart Failure (GDMT)

Eligibility

Locations

Lead Scientists at University of California Health

  • Hilary Shapiro, MD (ucsd)
    Assistant Clinical Professor, Medicine, Vc-health Sciences-schools
  • Afshan Hameed, MD (uci)
    Health Sciences Professor, Obstetrics and Gynecology, School of Medicine. Authored (or co-authored) 65 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Dennis M. McNamara, MD, MS
ID
NCT05180773
Phase
Phase 4 Cardiomyopathy Research Study
Study Type
Interventional
Participants
Expecting 250 study participants
Last Updated